GNPX
Genprex, Inc. NASDAQ$0.92
Mkt Cap $856,246
52w Low $0.86
0.1% of range
52w High $55.00
50d MA $1.66
200d MA $5.87
P/E (TTM)
-0.1x
EV/EBITDA
0.4x
P/B
0.1x
Debt/Equity
0.0x
ROE
-203.8%
P/FCF
-0.1x
RSI (14)
—
ATR (14)
—
Beta
-0.67
50d MA
$1.66
200d MA
$5.87
Avg Volume
1.0M
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -13.00 | -1.15 | +91.2% | 1.77 | -2.3% | +2.3% | -10.7% | -13.0% | -18.1% | -22.6% | -50.8% | — |
| Nov 14, 2025 | AMC | -12.50 | -5.00 | +60.0% | 4.43 | +0.0% | -8.8% | -16.7% | -24.6% | -28.7% | -32.3% | -41.8% | — |
| Aug 14, 2025 | AMC | -21.00 | -8.50 | +59.5% | 10.80 | +0.1% | -1.8% | -11.6% | -21.2% | -24.5% | -33.4% | +27.4% | — |
| May 12, 2025 | AMC | -0.82 | -0.26 | +68.3% | 13.80 | +1.5% | +2.2% | -19.2% | -14.2% | -10.4% | -2.2% | +11.5% | — |
| Apr 7, 2025 | AMC | -0.82 | -1.15 | -40.2% | 15.51 | +4.8% | -17.9% | -11.3% | -14.6% | -14.1% | -14.7% | -9.7% | — |
| Nov 13, 2024 | AMC | -1.13 | -1.23 | -8.8% | 80.00 | +2.5% | +2.5% | +0.0% | -15.0% | -19.4% | -31.2% | -27.5% | — |
| Aug 9, 2024 | AMC | -2.30 | -3.00 | -30.4% | 71.00 | +4.9% | -11.3% | -40.1% | -48.6% | -54.1% | -54.4% | -67.3% | — |
| May 15, 2024 | AMC | -2.54 | -3.69 | -45.3% | 125.50 | -1.2% | -3.6% | +1.6% | -2.8% | -6.4% | -5.6% | -13.5% | — |
| Mar 29, 2024 | AMC | -3.93 | -3.96 | -0.8% | — | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -0.11 | -5.20 | -4627.3% | 470.00 | +1.5% | +10.6% | +1.4% | +5.3% | +10.4% | +9.7% | -5.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $121.00 | $124.50 | +2.9% | +5.4% | +0.8% | -2.9% | -2.1% | -8.7% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $128.50 | $127.00 | -1.2% | -2.3% | -5.8% | -0.8% | -5.1% | -8.6% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $155.50 | $157.50 | +1.3% | -3.9% | -3.5% | -4.8% | -1.3% | -7.4% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $142.00 | $144.50 | +1.8% | +9.5% | +5.3% | +5.6% | +4.2% | +8.1% |
Recent Filings
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex secured an Israeli patent for its Reqorsa gene therapy combined with PD-1 antibodies in cancer treatment, strengthening its intellectual property portfolio and competitive position in immunotherapy.
Apr 30
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex's diabetes gene therapy candidate GPX-002 will present positive preclinical data at the 2026 ASGCT conference, potentially validating its therapeutic approach and supporting future clinical development.
Apr 28
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex partnered with UT MD Anderson to conduct biomarker research on its lead lung cancer gene therapy candidate Reqorsa, potentially enabling patient stratification for future clinical trials.
Apr 21
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
GNPX's TUSC2 therapeutic candidate shows concerning 50% resistance rate in lung cancer cell lines, potentially limiting its market addressable population and clinical viability.
Mar 18
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex secured patent protection in Japan and Europe for Reqorsa combination therapies with checkpoint inhibitors, strengthening its intellectual property position and potential commercial exclusivity for cancer treatments.
Feb 23
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex received Australian patent acceptance for its Reqorsa gene therapy combined with PD-L1 antibodies for cancer treatment, strengthening its intellectual property protection across multiple jurisdictions.
Feb 10
Data updated apr 25, 2026 11:52am
· Source: massive.com